Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma – guidance (TA677)

NICE recommends this treatment for use within the Cancer Drugs Fund as an option for relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton's tyrosine kinase inhibitor. Conditions in the managed access agreement for this treatment must be followed.

Source:

National Institute for Health and Care Excellence